Human Genome Sciences Inc. could earn more than half a billion dollars per terms of a newly formed agreement with Novartis AG on Albuferon (albumin-interferon alpha 2b), a product expected to move into Phase III for chronic hepatitis C by the end of this year. (BioWorld Today) Read More